Thus, targeting inhibition of IFITM3 and breaking this negative feedback loop for IFN-γ-mediated antitumor immunosuppression could be an option to modulate the tumor immune microenvironment in gastrointestinal tumors for therapies. The gene discussed is IFNG; the disease is digestive system neoplasm.